ATE371667T1 - Kahalalide f und verwandte verbindungen - Google Patents

Kahalalide f und verwandte verbindungen

Info

Publication number
ATE371667T1
ATE371667T1 AT01904169T AT01904169T ATE371667T1 AT E371667 T1 ATE371667 T1 AT E371667T1 AT 01904169 T AT01904169 T AT 01904169T AT 01904169 T AT01904169 T AT 01904169T AT E371667 T1 ATE371667 T1 AT E371667T1
Authority
AT
Austria
Prior art keywords
kahalalide
related compounds
leads
preparing
biological activity
Prior art date
Application number
AT01904169T
Other languages
English (en)
Inventor
Fernando Albericio
Ernest Giralt
Jose Jimenez
Angel Lopez
Ignacio Manzanares
Ignacio Rodrigues
Miriam Royo
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE371667T1 publication Critical patent/ATE371667T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Detergent Compositions (AREA)
AT01904169T 2000-02-09 2001-02-09 Kahalalide f und verwandte verbindungen ATE371667T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds

Publications (1)

Publication Number Publication Date
ATE371667T1 true ATE371667T1 (de) 2007-09-15

Family

ID=9885232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01904169T ATE371667T1 (de) 2000-02-09 2001-02-09 Kahalalide f und verwandte verbindungen

Country Status (28)

Country Link
US (2) US7482429B2 (de)
EP (3) EP1829889A3 (de)
JP (1) JP5188665B2 (de)
KR (1) KR100871489B1 (de)
CN (2) CN1422278A (de)
AT (1) ATE371667T1 (de)
AU (1) AU783542B2 (de)
BG (1) BG65926B1 (de)
BR (1) BR0108213A (de)
CA (1) CA2399187C (de)
CY (1) CY1106992T1 (de)
CZ (1) CZ304258B6 (de)
DE (1) DE60130192T2 (de)
DK (1) DK1254162T3 (de)
ES (1) ES2292558T3 (de)
GB (1) GB0002952D0 (de)
HK (1) HK1047290A1 (de)
HU (1) HUP0301817A3 (de)
IL (2) IL150981A0 (de)
MX (1) MXPA02007760A (de)
NO (1) NO331847B1 (de)
NZ (1) NZ520488A (de)
PL (1) PL207121B1 (de)
PT (1) PT1254162E (de)
RU (1) RU2280039C2 (de)
SK (1) SK11242002A3 (de)
UA (1) UA76949C2 (de)
WO (1) WO2001058934A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
DE60116359T2 (de) 2000-10-31 2006-09-28 Pharma Mar S.A. Kahalalid f formulierung
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CN100396696C (zh) * 2004-04-23 2008-06-25 中国科学院海洋研究所 一种海洋绿藻在提取抗肿瘤活性环肽组分中的应用
EP2207561A2 (de) * 2007-10-19 2010-07-21 Pharma Mar, S.A. Verbesserte antitumorale behandlungen
JP2011515330A (ja) * 2008-01-30 2011-05-19 ファルマ・マール・ソシエダード・アノニマ 改良抗腫瘍治療剤
RU2010140890A (ru) * 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные способы противоопухолевого лечения
CN103641891B (zh) * 2013-05-23 2017-03-22 深圳翰宇药业股份有限公司 一种制备Kahalalide F的方法
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
BR112019020464A2 (pt) 2017-03-30 2020-04-28 Xw Laboratories Inc. compostos derivados de heteroarila bicíclica, composição farmacêutica compreendendo os ditos compostos, adesivo transdérmico compreendendo a dita composição e uso terapêutico dos compostos e composição
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN112004802B (zh) 2018-09-30 2021-12-28 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
CA3162919A1 (en) 2019-12-20 2021-06-24 XWPharma Ltd. Methods of synthesizing 4-valyloxybutyric acid
CA3183185A1 (en) 2020-06-18 2021-12-23 Jia-Ning Xiang Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
CA3194665A1 (en) 2020-10-05 2022-04-14 Jia-Ning Xiang Modified release compositions of a gamma-hydroxybutyric acid derivative
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
US20230382851A1 (en) * 2022-04-21 2023-11-30 Zevra Therapeutics, Inc. Gamma-hydroxybutyrate delivering compounds and processes for making and using them

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39496A (en) * 1863-08-11 Improvement in ratchet-drills
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
JP4386967B2 (ja) * 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7476198A (en) * 1997-05-09 1998-11-27 General Hospital Corporation, The Cell proliferation related genes
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
IL143089A0 (en) * 1998-11-19 2002-04-21 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
CA2406743A1 (en) * 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
DE60116359T2 (de) 2000-10-31 2006-09-28 Pharma Mar S.A. Kahalalid f formulierung
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Also Published As

Publication number Publication date
JP5188665B2 (ja) 2013-04-24
PL207121B1 (pl) 2010-11-30
WO2001058934A2 (en) 2001-08-16
CZ304258B6 (cs) 2014-02-05
MXPA02007760A (es) 2002-10-23
KR100871489B1 (ko) 2008-12-05
SK11242002A3 (sk) 2003-06-03
UA76949C2 (en) 2006-10-16
KR20020092951A (ko) 2002-12-12
NO20023749L (no) 2002-10-07
BG65926B1 (bg) 2010-05-31
US20080318849A1 (en) 2008-12-25
CN1422278A (zh) 2003-06-04
CY1106992T1 (el) 2012-09-26
NO20023749D0 (no) 2002-08-08
AU783542B2 (en) 2005-11-10
AU3208601A (en) 2001-08-20
IL150981A0 (en) 2003-02-12
US20040214755A1 (en) 2004-10-28
ES2292558T3 (es) 2008-03-16
IL150981A (en) 2013-05-30
CA2399187C (en) 2011-04-19
HUP0301817A2 (hu) 2003-09-29
CN101597326B (zh) 2014-07-09
BG107020A (bg) 2003-05-30
CZ20022740A3 (cs) 2003-01-15
WO2001058934A3 (en) 2002-03-21
NO331847B1 (no) 2012-04-23
CN101597326A (zh) 2009-12-09
NZ520488A (en) 2005-03-24
BR0108213A (pt) 2003-03-05
RU2002123877A (ru) 2004-01-10
GB0002952D0 (en) 2000-03-29
EP1254162B1 (de) 2007-08-29
DK1254162T3 (da) 2008-01-02
PL356800A1 (en) 2004-07-12
HUP0301817A3 (en) 2011-10-28
EP1829889A2 (de) 2007-09-05
DE60130192D1 (de) 2007-10-11
PT1254162E (pt) 2007-12-03
RU2280039C2 (ru) 2006-07-20
DE60130192T2 (de) 2008-05-21
HK1047290A1 (en) 2003-02-14
JP2003522198A (ja) 2003-07-22
EP1254162A2 (de) 2002-11-06
EP1829889A3 (de) 2007-09-26
EP2258715A1 (de) 2010-12-08
US7482429B2 (en) 2009-01-27
CA2399187A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
ATE371667T1 (de) Kahalalide f und verwandte verbindungen
DK1161452T3 (da) Kovalent forbundne insulindimerer
AR009742A1 (es) Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su preparacion
AU9475001A (en) Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
DE60009511D1 (de) Nematizide trifluorbutene
ATE326551T1 (de) Dns-sonde spezifisch für staphylococcus epidermidis
ATE178803T1 (de) Verbindungen und artikel zur geruchsbegrenzung
NO905264L (no) Fremgangsmaate for fremstilling av biologisk aktivt protein
DE69131589D1 (de) Ribosomen-inaktivierende Proteine, inaktive Vorläuferformen derselben, Verfahren zur Herstellung und eine Methode zur Nutzung
ATE280242T1 (de) Verfahren zum nachweis von bakterien
NL300229I2 (nl) Werkwijze voor het zuiveren van keratinocytgroeifactoren.
ATE220420T1 (de) Biokatalytische metoden zum synthetisieren und identifizieren biologisch aktive verbindungen
DE69027191D1 (de) N-oxygenierte Arylpyrrole als insektizide, akarizide und nematizide Wirkstoffe
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
ATE247085T1 (de) Verbindungen verwendbar zur perhaloalkylierung, reagenz für ihrer durchführung und verfahren zu ihrer herstellung
DE69228438D1 (de) Mikrobielles Verfahren zur Herstellung von Trans-4-hydroxy-L-Prolin
DE69107546D1 (de) Verfahren zur Herstellung von Insektiziden, Akariziden und Nematiziden-2-Aryl-5-(trifluormethyl)-Pyrrolen.
DE60023324D1 (de) Zusammensetzung zur in-vitro befruchtung
DE59809481D1 (de) Verfahren zur Herstellung von Aminocyanacetamid
DE69117438D1 (de) Verfahren zur Herstellung von insektiziden, nematiziden und akariziden, in 4-Stellung substituierten 5-(Trifluormethyl) pyrrol-3-nitril-Verbindungen
ATE277173T1 (de) Immobilisiertes enzym und verfahren zur herstellung von optisch aktiven cyanhydrinen
ES2095544T3 (es) Metodo para la preparacion de compuestos de 2-aril-5-trifluormetilpirrol.
ID22910A (id) Metode untuk memproduksi fibrinogen
DE69004320D1 (de) Hydroxyphenethylamin-Derivat und dessen Salze, Verfahren zur Herstellung, medizinische Verwendung und Verwendung als spezifisches pharmakologisches Werkzeug.
DE3882654D1 (de) Enzymhemmer und methode zu dessen herstellung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1254162

Country of ref document: EP